Cancer stem cells and HER2 positive breast cancer: The story so far

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• HER2+ breast cancer is characterized by Human Epidermal Growth Factor Receptor type 2 (HER2) gene amplification/overexpression.
• While anti-HER2 therapies have improved prognosis, drug resistance and tumor recurrence remain significant clinical challenges.
• Cancer Stem Cells (CSCs) are implicated in treatment resistance and tumor persistence in various cancers.

Purpose of the Study:

• To provide a comprehensive overview of Cancer Stem Cells (CSCs) in the context of HER2+ breast cancer.
• To elucidate the markers for CSC identification and associated signaling pathways in HER2+ breast cancer.
• To explore the interaction between HER2 and signaling pathways in CSCs and discuss future therapeutic strategies targeting CSCs.

Main Methods:

• Literature review synthesizing current knowledge on CSCs in HER2+ breast cancer.
• Identification and description of key markers used for CSC isolation and characterization.
• Elucidation of signaling pathways implicated in HER2+ breast CSCs and their interaction with HER2.

Main Results:

• CSCs are a critical cell population contributing to drug resistance and recurrence in HER2+ breast cancer.
• Specific markers and signaling pathways are associated with the maintenance and function of HER2+ breast CSCs.
• HER2 signaling pathways are intricately linked with CSC-associated pathways, influencing tumor behavior.

Conclusions:

• Understanding CSCs and their associated pathways is crucial for addressing treatment resistance in HER2+ breast cancer.
• Targeting CSCs, potentially in combination with anti-HER2 therapies, holds significant promise for improving clinical outcomes.
• Further research into HER2-CSC interactions may reveal novel therapeutic targets to eradicate residual disease and prevent recurrence.